Acorda Therapeutics Begins Second Phase 1 GGF2 Trial In Heart Failure NASDAQ (RTTNews.com) - Acorda Therapeutics Inc. ( ACOR ) today announced that the first patient has been enrolled in the second trial of Glial Growth Factor 2 or GGF2. This Phase 1b single-infusion study in people with heart failure would evaluate ... Aegis Capital Keeps Buy on Acorda (ACOR); GGF2 Progress In-Line, Q3 Should ... |
